* Protagonist Therapeutics Inc PTGX.OQ reported quarterly
adjusted earnings of $3.26 per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -67 cents. The mean expectation of
five analysts for the quarter was for earnings of $1.19 per
share. Wall Street expected results to range from -62 cents
to $3.95 per share.
* Revenue was $254.95 million; analysts expected $120.00
million.
* Protagonist Therapeutics Inc's reported EPS for the
quarter was
$3.26.
* The company reported quarterly net income of $207.34
million.
* Protagonist Therapeutics Inc shares had fallen by 10.9%
this
quarter and gained 12.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 76.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $45.00
This summary was machine generated from LSEG data May 8 at 07:39
a.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 1.19 3.26 Beat
Dec. 31 2023 -0.03 0.44 Beat
Sep. 30 2023 -0.69 -0.58 Beat
Jun. 30 2023 -0.65 -0.68 Missed